Back to search

University of Ioannina

Σύγκριση συνδυασμών υπολιπιδαιμικών φαρμάκων σε ασθενείς με μικτή δυσλιπιδαιμία

Abstract

dc:description

Introduction: Mixed dyslipidemia is characterized by elevated levels of triglycerides (TGs), low levels of high-density lipoprotein cholesterol (HDL-C) and increased low-density lipoprotein cholesterol (LDL-C) concentration. Furthermore, it is associated with increased levels of the atherogenic small dense (sd) LDL particles. Mixed dyslipidemia can be a therapeutic challenge as monotherapy with conventional statin doses may only partially correct all underlying metabolic defects. The next step in patients with mixed dyslipidemia not on treatment goals despite treatment with a statin at a standard dose remains debatable. Switch to the highest approved dose of rosuvastatin (40 mg) or addition of fenofibrate or extended release nicotinic acid (ER-NA)/laropiprant (LRPT) comprises 3 possible options. Aim of the study: Aim of the study was the comparison of switch to the highest approved dose of rosuvastatin (40 mg) or the addition of fenofibrate or ER-NA/LRPT in patients with mixed dyslipidemia who were treated with a standard statin dose but had not achieved lipid targets, regarding their effect on lipid profile, metabolic parameters and other cardiovascular risk markers. Patients and Methods: We recruited 100 patients with mixed dyslipidemia who were treated with a statin at a standard dose but had not achieved lipid targets. Patients were randomized to switch to rosuvastatin 40 mg, add-on ER-NA/ LRPT (1000/20 mg/day for the first 4 weeks followed by 2000/40 mg/day for the next 8 weeks) or to add-on micronized fenofibrate (200 mg/day) for 3 months. Before the intervention and after 3 months the following parameters were assessed: 1] lipid profile, 2] cholesterol levels of LDL and HDL subfractions and mean LDL particle size, 3] lipoprotein-associated phospholipase A2 (Lp-PLA2) activity, 4] oxidative stress markers [high sensitivity C reactive protein (hs-CRP), F2-isoprostane (8-iso-PGF2a), oxidized (ox) LDL], 5] non-lipid metabolic parameters [uric acid levels (UA), fasting glucose and insulin, ΗΟΜΑ-IR (Homeostasis Model Assessment Insulin Resistance) index], 6] renal function [estimated glomerular filtration rate (eGFR)] and renal protein excretion, 7] blood pressure levels, 8] safety.Results: 1] Switch to the highest dose of rosuvastatin and add-on ER-NA/LRPT were associated with similar reductions in non-HDL-C and LDL-C. On the contrary add-on fenofibrate was associated with a smaller non-HDL-C reduction, compared with the other 2 therapeutic groups, while no change in LDL-C levels was reported in the add-on fenofibrate group. However add-on-fenofibrate was associated with greater decrease in TGs and increase in HDL-C compared with rosuvastatin 40 mg. Add-on ER-NA/LRPT was associated with greater HDL-C increase, while both add-on ER-NA/LRPT and fenofibrate were associated with greater TGs reduction compared with rosuvastatin monotherapy. Only add-on ER-NA/LRPT was associated with significant reduction in lipoprotein a [Lp(a)] levels, 2] All therapeutic interventions were associated with similar sd-LDL-C reduction and similar increase in mean LDL particle size. Add-on ER-NA/LRPT was associated with increased large HDL-C, while small HDL-C was decreased. On the contrary, add-on fenofibrate was associated with increased small HDL-C and decreased large HDL-C. Rosuvastatin monotherapy was associated with a small increase in large HDL-C. 3] All therapeutic interventions were associated with decreased LpPLA2 activity. This reduction was greater in the add-on ER-NA/LRPT group compared with the rest 2 groups. HDL-Lp-PLA2 activity increased in all groups but this increase was greater in the add-on ER-NA/LRPT group followed by the add-on fenofibrate group. 3] Rosuvastatin monotherapy and add-on ER-NA/LRPT groups were associated with the greatest reductions in hs-CRP levels, while add-on fenofibrate was not associated with any change in hs-CRP concentration. Plasma 8-epi PGF2α were similarly reduced in all groups. Urine 8-epi PGF2α and serum ox-LDL were similarly decreased in rosuvastatin monotherapy and add-on ER-NA/LRPT groups, while a smaller reduction was observed in add-on fenofibrate group. 5] Apart from an observed phosphate reduction in the add-on ER-NA/LRPT group, no significant change was observed in electrolytes in any group. Add-on ER-NA/LRPT was associated with increased serum uric acid levels, while add-on fenofibrate was associated with reduced serum uric acid levels and rosuvastatin monotherapy did not affect this parameter. Add-on ER-NA/LRPT and to a lesser extend rosuvastatin monotherapy deteriorated glycemic profile, while add-on fenofibrate decreased insulin resistance. 6] Add-on fenofibrate was associated with eGFR reduction, while no change was reported in the other groups. No intervention was associated with any change in renal protein excretion. 7] Contrary to the switch to high-dose rosuvastatin 40 mg and the add-on fenofibrate, the addition of ER-NA/LRPT to statin treatment was associated with significant reductions in both systolic and diastolic blood pressure. 8] Of the 100 patients enrolled, 8 (24%) of the 34 initially randomized to the add-on ER-NA/LRPT group dropped out during the study because of flushing (N = 5), epigastric pain (N = 2) and new onset diabetes (N = 1). Also, 1 (3%) patient of the 33 initially randomized to the rosuvastatin 40 mg group dropped out because of asymptomatic, threefold alanine aminotransferase (ALT) elevation and 1 (3%) patient of the 33 randomized in the add-on fenofibrate group because of serum creatinine elevation (> 20% from baseline). Conclusion: Switch to the highest dose of rosuvastatin and add-on ER-NA/LRPT may be better options compared with add-on fenofibrate for the management of patients with mixed dyslipidemia not on treatment goals with a standard statin dose. However, ER-NA/LRPT is associated with a significant number of adverse events (flushing, deterioration of glycemic profile, epigastric pain, myopathy), while it has failed to prove benefit in the most recent prospective clinical trials. Thus, in the clinical setting switch to high dose of a potent statin such as 40 mg of rosuvastatin comprises a better therapeutic approach in this patient population.

Degree

thesis:*
Grantor dc:publisher
University of Ioannina
Year dc:date
2017

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Kei, Anastazia
  • Κεή, Αναστάζια

Subjects

dc:subject × 16

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/44722

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Kei, Anastazia; Κεή, Αναστάζια. Σύγκριση συνδυασμών υπολιπιδαιμικών φαρμάκων σε ασθενείς με μικτή δυσλιπιδαιμία. University of Ioannina, 2017. http://hdl.handle.net/10442/hedi/44722